Search research articles
Contact Us
Filters
Showing results (61-70 of 81) with videos related to
Page
of 9
Sort By:
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
June 25, 2011
Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab
Thomas E Delea, Paul Tappenden, Oleg Sofrygin, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 5, 2017
The Type and Impact of Evidence Review Group Exploratory Analyses in the NICE Single Technology Appraisal Process
Christopher Carroll, Eva Kaltenthaler, Daniel Hill-McManus, et al.
Pharmacoeconomics
|
April 30, 2016
A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy
Paul Tappenden, Shijie Ren, Rachel Archer, et al.
International Journal of Technology Assessment in Health Care
|
October 14, 2014
Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers
Oriana Ciani, Sarah Davis, Paul Tappenden, et al.
Health Technology Assessment (Winchester, England)
|
July 3, 2019
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis
Sue Harnan, Paul Tappenden, Katy Cooper, et al.
Pharmacoeconomics
|
February 9, 2017
Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Paul Tappenden, Christopher Carroll, John W Stevens, et al.
Health Technology Assessment (Winchester, England)
|
October 11, 2025
Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review and economic evaluation
Paul Tappenden, Katy Cooper, Jean Hamilton, et al.
BMC Health Services Research
|
March 21, 2013
Using resource modelling to inform decision making and service planning: the case of colorectal cancer screening in Ireland
Linda Sharp, Lesley Tilson, Sophie Whyte, et al.
Breast Cancer Research and Treatment
|
February 3, 2025
Gene expression profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review
Katy Cooper, Gamze Nalbant, Munira Essat, et al.
Health Technology Assessment (Winchester, England)
|
May 26, 2016
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model
Rachel Archer, Paul Tappenden, Shijie Ren, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 81) with videos related to
Sort By:
Page
of 9
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
June 25, 2011
Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab
Thomas E Delea, Paul Tappenden, Oleg Sofrygin, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 5, 2017
The Type and Impact of Evidence Review Group Exploratory Analyses in the NICE Single Technology Appraisal Process
Christopher Carroll, Eva Kaltenthaler, Daniel Hill-McManus, et al.
Pharmacoeconomics
|
April 30, 2016
A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy
Paul Tappenden, Shijie Ren, Rachel Archer, et al.
International Journal of Technology Assessment in Health Care
|
October 14, 2014
Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers
Oriana Ciani, Sarah Davis, Paul Tappenden, et al.
Health Technology Assessment (Winchester, England)
|
July 3, 2019
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis
Sue Harnan, Paul Tappenden, Katy Cooper, et al.
Pharmacoeconomics
|
February 9, 2017
Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Paul Tappenden, Christopher Carroll, John W Stevens, et al.
Health Technology Assessment (Winchester, England)
|
October 11, 2025
Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review and economic evaluation
Paul Tappenden, Katy Cooper, Jean Hamilton, et al.
BMC Health Services Research
|
March 21, 2013
Using resource modelling to inform decision making and service planning: the case of colorectal cancer screening in Ireland
Linda Sharp, Lesley Tilson, Sophie Whyte, et al.
Breast Cancer Research and Treatment
|
February 3, 2025
Gene expression profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review
Katy Cooper, Gamze Nalbant, Munira Essat, et al.
Health Technology Assessment (Winchester, England)
|
May 26, 2016
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model
Rachel Archer, Paul Tappenden, Shijie Ren, et al.
Page
of 9